Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZYN002 in Fragile X Syndrome
NCT03614663Phase 3Completed
- Sponsor
- Zynerba Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Jun 2020
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in Fragile X syndrome (FXS) comparing Zygel with Placebo (2 arms). Primary endpoint: Aberrant Behavior Checklist-Community Fragile X Factor Structure Social Avoidance Subscale at 12 weeks. Started Jun 2018; status: completed.
02
Drugs
Zygel
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT03614663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03614663.